ATE446101T1 - Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung - Google Patents

Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung

Info

Publication number
ATE446101T1
ATE446101T1 AT04075413T AT04075413T ATE446101T1 AT E446101 T1 ATE446101 T1 AT E446101T1 AT 04075413 T AT04075413 T AT 04075413T AT 04075413 T AT04075413 T AT 04075413T AT E446101 T1 ATE446101 T1 AT E446101T1
Authority
AT
Austria
Prior art keywords
senil
dementia
alzheimer
disease
treatment
Prior art date
Application number
AT04075413T
Other languages
English (en)
Inventor
David John Kyle
Original Assignee
Martek Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22114083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE446101(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Martek Biosciences Corp filed Critical Martek Biosciences Corp
Application granted granted Critical
Publication of ATE446101T1 publication Critical patent/ATE446101T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Polymers & Plastics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
AT04075413T 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung ATE446101T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7350593A 1993-06-09 1993-06-09

Publications (1)

Publication Number Publication Date
ATE446101T1 true ATE446101T1 (de) 2009-11-15

Family

ID=22114083

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04075413T ATE446101T1 (de) 1993-06-09 1994-06-02 Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
AT94918217T ATE264099T1 (de) 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94918217T ATE264099T1 (de) 1993-06-09 1994-06-02 Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen

Country Status (11)

Country Link
EP (3) EP2140863A1 (de)
JP (3) JPH08511533A (de)
AT (2) ATE446101T1 (de)
AU (1) AU693450B2 (de)
CA (2) CA2596241C (de)
DE (2) DE69435246D1 (de)
DK (1) DK0707487T3 (de)
ES (2) ES2335991T3 (de)
MX (1) MX263227B (de)
PT (1) PT707487E (de)
WO (1) WO1994028913A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658767A (en) * 1991-01-24 1997-08-19 Martek Corporation Arachidonic acid and methods for the production and use thereof
US5583019A (en) * 1995-01-24 1996-12-10 Omegatech Inc. Method for production of arachidonic acid
WO1996033263A1 (en) * 1995-04-17 1996-10-24 JAPAN, represented by DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY Novel microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms
EP1886679A3 (de) * 1995-06-07 2008-05-28 Martek Biosciences Corporation Verfahren zur Regulierung des Gehalts an mehrfach ungesättigten Fettsäuren in verschiedenen Geweben
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
CN1217029A (zh) * 1996-03-28 1999-05-19 吉斯特-布罗卡迪斯股份有限公司 从用巴氏法灭菌的生物量中制备含有微生物多不饱和脂肪酸的油的方法
WO1997039759A2 (en) * 1996-04-24 1997-10-30 Brigham And Women's Hospital Omega-3 fatty acids and omega-3 phosphatidylcholine in the treatment of bipolar disorder
ES2175409T5 (es) * 1996-05-15 2007-05-01 Dsm Ip Assets B.V. Extraccion de esterol con un disolvente polar para dar un aceite microbiano bajo en esterol.
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
JP3792309B2 (ja) 1996-08-30 2006-07-05 サントリー株式会社 不飽和脂肪酸含有油脂の製造方法
JP4633204B2 (ja) * 1996-10-11 2011-02-16 サントリーホールディングス株式会社 アラキドン酸含有食用油脂およびそれを含有する食品
US6344482B1 (en) 1997-04-23 2002-02-05 Andrew L. Stoll Omega-3 fatty acids in the treatment of bipolar disorder
US6852870B2 (en) 1999-03-22 2005-02-08 Andrew Stoll Omega-3 fatty acids in the treatment of depression
US5993221A (en) * 1997-05-01 1999-11-30 Beth Israel Deaconess Medical Center, Inc. Dietary formulation comprising arachidonic acid and methods of use
FR2782921B1 (fr) * 1998-09-09 2002-09-20 Dior Christian Parfums Extrait lipidique de l'algue skeletonema, procede de preparation et utilisation dans des domaines cosmetique et pharmaceutique, notamment dermatologique
AU775421B2 (en) * 1998-10-15 2004-07-29 Dsm Ip Assets B.V. Pufa supplements
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
EP1178103A1 (de) 2000-08-02 2002-02-06 Dsm N.V. Reinigung von rohen PUFA-reichen Ölen
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
US8729124B2 (en) 2002-03-05 2014-05-20 Pronova Biopharma Norge As Use of EPA and DHA in secondary prevention
BRPI0311906B1 (pt) 2002-06-19 2017-02-21 Dsm Ip Assets Bv processo para obtenção de um ácido graxo poliinsaturado (pufa) ou um óleo microbiano de células microbianas
EP2295529B2 (de) 2002-07-11 2022-05-18 Basf As Verfahren zur Verminderung von Umweltschadstoffen in einem Öl oder einem Fett und Fischfutterprodukt
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
BR0314799A (pt) 2002-09-27 2005-07-26 Market Biosciences Corp Controle glicêmico aperfeiçoado para pré-diabetes e/ou diabetes do tipo ii usando ácido docosahexaenóico
EP2283837A3 (de) 2002-09-27 2011-04-20 Martek Biosciences Corporation Docosahexaensäure zur Behandlung von subklinischen Entzündungen
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP5503846B2 (ja) * 2005-01-24 2014-05-28 プロノヴァ・バイオファーマ・ノルゲ・アーエス アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、ｄｈａを含有する脂肪酸組成物の使用
US8324276B2 (en) 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
ES2624702T5 (es) * 2005-05-23 2020-12-11 Massachusetts Inst Technology Composiciones que contienen PUFA y/o uridina y métodos para su uso
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
FR2894772B1 (fr) * 2005-12-20 2008-03-14 Pierre Fabre Medicament Sa Procede d'enrichissement en dha
ES2277557B1 (es) * 2005-12-21 2008-07-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo.
EP1962825B1 (de) * 2005-12-21 2014-04-02 Brudy Technology, S.L. Verwendung von dha zur behandlung von erkrankungen in zusammenhang mit oxidativen zellschäden
NL1032840C2 (nl) * 2006-11-09 2008-05-13 Friesland Brands Bv Probiotische hydrolysaatvoeding voor kinderen.
JPWO2008081989A1 (ja) 2006-12-28 2010-04-30 サントリーホールディングス株式会社 神経再生剤
DE102007031039A1 (de) * 2007-07-04 2009-01-08 Süd-Chemie AG Verfahren zur schonenden Raffination von Pflanzenölen mit Naturbleicherde
CN102365087A (zh) * 2009-02-02 2012-02-29 马太克生物科学公司 改善认知功能和降低心率的方法
DK3530740T3 (da) * 2009-03-19 2021-10-18 Dsm Ip Assets Bv Thraustochytrider, fedtsyresammensætninger og fremgangsmåder til fremstilling deraf og anvendelser deraf
GB0907601D0 (en) * 2009-05-01 2009-06-10 Equateq Ltd Novel methods
JP5911479B2 (ja) * 2010-06-01 2016-04-27 ディーエスエム アイピー アセッツ ビー．ブイ． 細胞からの脂質の抽出およびそれに由来する生産物
WO2012090625A1 (ja) * 2010-12-28 2012-07-05 医療法人社団ブックス 認知症を血液サンプルで判定するための検査方法
CN103732223A (zh) * 2011-05-19 2014-04-16 加利福尼亚大学董事会 用于认知能力下降的医疗食品
MY169454A (en) * 2011-07-21 2019-04-11 Dsm Ip Assets Bv Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
JP5496163B2 (ja) * 2011-10-19 2014-05-21 サントリーホールディングス株式会社 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
FR2991337B1 (fr) * 2012-05-29 2016-09-02 Roquette Freres Procede continu d'enrichissement en esters ethyliques de dha d'une huile produite par des microalgues
ES2984970T3 (es) 2013-12-20 2024-10-31 Mara Renewables Corp Métodos para recuperar aceite de microorganismos
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
ES2967076T3 (es) 2016-11-17 2024-04-25 Univ Of Debrecen Compuestos precursores para proporcionar retinoides de la vía de la vitamina a5 y sus usos
AU2017380721B2 (en) 2016-12-22 2021-04-01 MARA Renewables Corporation Methods for producing biomass rich in DHA, palmitic acid and protein using a eukaryotic microorganism
KR101946362B1 (ko) * 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물
MX2022012322A (es) 2020-04-03 2022-11-10 Mara Renewables Corp Aceites microbianos con niveles altos de ácidos grasos omega-3.

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5198468A (en) * 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
WO1989000606A1 (en) * 1987-07-20 1989-01-26 Maricultura, Incorporated Microorganism production of omega-3 (n-3) lipids
JP2524217B2 (ja) * 1988-04-18 1996-08-14 マルハ株式会社 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤または痴呆治療剤
JPH01279827A (ja) * 1988-05-02 1989-11-10 Taiyo Fishery Co Ltd 脳機能改善組成物、学習能力増強剤、記憶力増強剤、痴呆予防剤、痴呆治療剤、または脳機能改善効果を有する機能性食品
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5130242A (en) * 1988-09-07 1992-07-14 Phycotech, Inc. Process for the heterotrophic production of microbial products with high concentrations of omega-3 highly unsaturated fatty acids
JP2730081B2 (ja) * 1988-09-24 1998-03-25 日本油脂株式会社 微生物によるアラキドン酸含有油脂の製造方法
DE3920679A1 (de) * 1989-06-23 1991-01-10 Milupa Ag Fettmischung zur herstellung von nahrungen, insbesondere saeuglingsnahrungen
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
ZA92452B (en) * 1991-01-24 1992-10-28 Martek Corp Microbial oil mixtures and uses thereof
PH11992043811B1 (en) * 1991-01-24 2002-08-22 Martek Corp Arachidonic acid and methods for the production and use thereof
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
CA2121986A1 (en) * 1993-04-26 1994-10-27 Daizo Takeuchi Processes for culturing marine microalgae and producing docosahexaenoic acid using the same

Also Published As

Publication number Publication date
DK0707487T3 (da) 2004-08-02
ES2218525T3 (es) 2004-11-16
CA2596241C (en) 2011-04-19
DE69433713D1 (de) 2004-05-19
EP0707487A4 (de) 1998-09-02
JP2011121978A (ja) 2011-06-23
DE69435246D1 (de) 2009-12-03
MX263227B (en) 2008-12-17
AU6963594A (en) 1995-01-03
JPH08511533A (ja) 1996-12-03
AU693450B2 (en) 1998-07-02
EP2140863A1 (de) 2010-01-06
CA2596241A1 (en) 1994-12-22
WO1994028913A1 (en) 1994-12-22
JP2008133286A (ja) 2008-06-12
PT707487E (pt) 2004-08-31
EP0707487A1 (de) 1996-04-24
DE69433713T2 (de) 2005-04-07
EP0707487B1 (de) 2004-04-14
CA2164291A1 (en) 1994-12-22
ATE264099T1 (de) 2004-04-15
CA2164291C (en) 2007-10-30
EP1419780A1 (de) 2004-05-19
ES2335991T3 (es) 2010-04-07
EP1419780B1 (de) 2009-10-21

Similar Documents

Publication Publication Date Title
ATE446101T1 (de) Verwendung von docosahexaensäure zur herstellung eines arzneimittels zur behandlung der senilen demenz und alzheimer-erkrankung
ATE210979T1 (de) Verwendung rapamycin zur herstellung eines medikaments für die verbeugung und behandlung von hyperproliferativen gefässerkrankheiten, eventuell in kombination mit mycophenolsäure
ATE141505T1 (de) Verwendung von 3-guanidinopropionsäure zur herstellung eines medikaments zur behandlung und prävention von fettsucht
ATE204704T1 (de) Verwendung von bcl-2 zur herstellung von arzneimitteln zur therapeutischen behandlung und verhinderung von krankheiten
DE69636085D1 (de) Verwendung von gamma-Linolensäure oder Dihomogammalinolensäure zur Herstellung eines Medikaments zur Behandlung von Huntington's Chorea
ATE79264T1 (de) Verwendung von bismuth zur herstellung von medikamenten zur behandlung von magendarmst¯rungen, die von campylobacter polyridis verursacht sind.
ATE133336T1 (de) Verwendung von rapamycin zur herstellung eines arzneimittels zur behandlung von augenentzündungen
DE69012591D1 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69739792D1 (de) Verfahren zur Behandlung von Augenerkrankungen
ATE231885T1 (de) Verwendung von komplement-inhibitoren zur herstellung eines arzneimittels zur prophylaxe und therapie von entzündlichen darm- und hauterkrankungen sowie purpura
WO1996040106A3 (en) Methods for controlling highly unsaturated fatty acid content in various tissues
ATE120954T1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines arzneimittels zur behandlung von aids.
ATE142500T1 (de) Doppelsträngige rns zur korrektur von abnormalitäten von zirkulierenden immunkomplexen und der monozytenfunktion
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE274349T1 (de) Verwendung von fruktan zur herstellung eines arzneimittels zur vorbeugung und behandlung von dickdarmkrebs
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE69301750D1 (de) Verwendung von 1-Alpha,24(R)-Dihydroxy-22(E)-Dehydrovitamin-D3 zur Herstellung eines Arzneimittels zur Behandlung der Osteoporose
ATE143809T1 (de) Placentaextrakt und verfahren zu seiner herstellung
ATE226069T1 (de) Verwendung von alkanoyl-l-carnitinen zur herstellung eines arzneimittels zur behandlung von entzündlichen darmerkrankungen
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69630055D1 (de) Verwendung von olanzapin oder eines salzes für die herstellung eines medikaments für die behandlung von autismus und mentaler retardation
ATE139696T1 (de) Verwendung von benzothiazepinen zur herstellung von arzneimitteln zur behandlung von epileptischen anfällen
ATE150645T1 (de) Verwendung von bmy 14802 zur behandlung von angstzuständen bei patienten mit benzodiazepin- entzugserscheinungen
SE8700136L (sv) Forfarande for behandling av amfotera aminosyror

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties